ST-segment Elevation Myocardial Infarction
Conditions
Brief summary
Evaluate the efficacy, Safety and Pharmacokinetics of Intravenous single injection LC28-0126 immediately before Percutaneous Coronary Intervention (PCI) in Patients with ST-segment Elevation Myocardial Infarction (STEMI).
Interventions
DRUGPlacebo
Placebo
DRUGLC28-0126 Dose A
LC28-0126 Dose A
DRUGLC28-0126 Dose B
LC28-0126 Dose B
DRUGLC28-0126 Dose C
LC28-0126 Dose C
Sponsors
LG Life Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age between 20 and 75 * Within 12 hours after the onset of chest pain * ST-segment elevation of more than 0.1 mV in two contiguous leads or new left bundle-branch block (LBBB) patients * Signed for written informed consent
Exclusion criteria
* Left Main disease * Multi-vessel disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC of Troponin I for 72 hours post PCI | pre PCI, PCI 0h, 6h, 12h, 18h, 24h, 48h, 72h |
Secondary
| Measure | Time frame |
|---|---|
| AUC of CK-MB for 72 hours post PCI | pre PCI, PCI 0h, 6h, 12h, 18h, 24h, 48h, 72h |
| AUC of CK for 72 hours post PCI | pre PCI, PCI 0h, 6h, 12h, 18h, 24h, 48h, 72h |
| Infarct size assessed by Cardiac MRI | Day 4, 30 |
| Myocardial function assessed by Cardiac MRI | Day 4, 30 |
| Myocardial function assessed by Echocardiogram | Day 4, 30 |
Countries
South Korea
Outcome results
None listed